KIR3DL1 and hematologic disorder: The mismatch between KIR and HLA was also investigated by Wanquet et al., who studied 144 patients with hematologic malignancies treated with T cell—replete (without removing T cells) haploidentical stem cell transplantation (Haplo-SCT) with the use of post-transplant cyclophosphamide (PT-Cy).